

Haematologica  
HAEMATOL/2019/242891  
Version 3

Discontinuation of tyrosine kinase inhibitors in chronic myeloid  
leukemia: when and for whom?

Ehab Atallah and Charles A Schiffer

Disclosures: None.

Contributions: Both authors equally contributed